| 영문 | differentiation | 한글 | 분화 |
|---|---|---|---|
| 설명 | 세포가 분열, 증식하여 성장하는 동안에 구조나 기능이 서로 특수화하는 현상. 다세포생물 개체에서 기관이나 조직이나 세포간에 형태적 및 기능적 차이가 생기게 되는데, 예를 들면 개체발생에서 처음에는 동질이었던 부분에서 머리나 몸통 등의 구별이 생기고, 세포에서도 근세포, 신경세포 등의 구별이 생기는 상태를 말한다. 일반적으로 분화한 세포에서는 형태적 특수화와 더불어 분화의 지표가 되는 특이한 단백질 합성이 나타나기 때문에 분화는 유전자의 조절에 의해 나타난 결과라고 생각되고 있다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| EDF | eosinophil differentiation factor; erythroid differentiation factor; extradural fluid |
|---|---|
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| AML | Acute Myelogenous Leukemia Morphologic Classification(FAB분류) &n... |
| MMM | see 3-M [syndrome]; microsome-mediated mutagenesis; myelofibrosis with myeloid metaplasia; myeloscle... |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| MNDA | myeloid cell nuclear differentiation antigen |
|---|---|
| D factor | Differentiation-stimulating factor |
| EDF | A/erythroid differentiation factor |
| BCDF | B cell differentiation factor |
| DIF | Differentiation Inducing Factor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| acute myeloid leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
|---|---|
| agnogenic myeloid metaplasia | A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets. Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably. Origin: Gr. Plassein = to form (27 Sep 1997) |
| chronic myeloid leukaemia | <haematology> A leukaemia which is initially slowly-progressing. There are approximately 650 new cases each year in the UK. It is characterised by the presence of large numbers of abnormal mature granulocytes, circulating in the blood. Synonym: chronic granulocytic leukaemia. Acronym: CML Origin: Gr. Haima = blood (12 Jan 1998) |
| myeloid | Collective term for the nonlymphocyte groups of white blood cells. It includes cells from the granulocyte, monocyte and platelet lineages. (13 Nov 1997) |
| myeloid cell | <haematology, pathology> One of the two classes of marrow derived blood cells, includes megakaryocytes, erythrocyte precursors, mononuclear phagocytes and all the polymorphonuclear granulocytes. That all these are ultimately derived from one stem cell lineage is shown by the occurrence of the Philadelphia chromosome in these, but not lymphoid, cells. most authors tend, however, to restrict the term myeloid to mononuclear phagocytes and granulocytes and commonly distinguish a separate erythroid lineage. (12 May 1997) |
| myeloid metaplasia | A progressive disease of the bone marrow where neoplastic bone marrow stem cells lodge and grow in multiple sites outside the bone marrow. Typically, there is enlargement of the spleen and a gradual replacement of the bone marrow elements by fibrosis (scarring), progressive anaemia and variable changes in the number of white blood cells and platelets. Diagnosis is by bone marrow biopsy. There is no definitive treatment for this disorder that has been shown to affect life span favorably. Origin: Gr. Plassein = to form (27 Sep 1997) |
| myeloid sarcoma | <tumour> A malignant tumour of immature myeloid cells, frequently subperiosteal, associated with or preceding granulocytic leukaemia. See: chloroma. Synonym: myeloid sarcoma. (05 Mar 2000) |
| myeloid series | The granulocytic and the erythrocytic series. (05 Mar 2000) |
| myeloid tissue | Bone marrow consisting of the developmental and adult stages of erythrocytes, granulocytes, and megakaryocytes in a stroma of reticular cells and fibres, with sinusoidal vascular channels. (05 Mar 2000) |
| primary myeloid metaplasia | Myeloid metaplasia occurring as the primary condition, often in association with myelofibrosis. Synonym: agnogenic myeloid metaplasia. (05 Mar 2000) |
| secondary myeloid metaplasia | Myeloid metaplasia occurring in individuals with another disease. Synonym: symptomatic myeloid metaplasia. (05 Mar 2000) |
| symptomatic myeloid metaplasia | Myeloid metaplasia occurring in individuals with another disease. Synonym: symptomatic myeloid metaplasia. (05 Mar 2000) |
| leukaemia, myeloid | Form of leukaemia characterised by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites. (12 Dec 1998) |
| antigens, differentiation | Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation. (12 Dec 1998) |
| antigens, differentiation, b-lymphocyte | Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin. (12 Dec 1998) |
Synonyms : MyD88 Protein, TLR Signal Adaptor Protein MyD88, Toll-Like Receptor Signal Adaptor Protein MyD88, Toll Like Receptor Signal Adaptor Protein MyD88
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|